NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:05 pm EDT
Share
NovaBay Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 4.61 million compared to USD 3.66 million a year ago. Net loss was USD 2.04 million compared to USD 2.16 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.43 a year ago. Diluted loss per share from continuing operations was USD 1.27 compared to USD 1.43 a year ago.
For the six months, revenue was USD 7.73 million compared to USD 6.94 million a year ago. Net loss was USD 3.78 million compared to USD 2.27 million a year ago. Basic loss per share from continuing operations was USD 2.21 compared to USD 1.54 a year ago. Diluted loss per share from continuing operations was USD 2.21 compared to USD 1.54 a year ago.
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells consumer products for the eyecare and skincare markets. The Company's lead product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have antimicrobial properties as it removes foreign material, such as microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with its form of hypochlorous acid and is cleared by the United States Food and Drug Administration (FDA) for sale in the United States. Its other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress and the i-Chek. Avenova Spray is available both over-the-counter and as a prescription. Avenova Spray is also available at optometrists and ophthalmologists offices; at national pharmacy chains across all over 50 states, and through its Partner Pharmacy Program.